Last reviewed · How we verify
NCT05105490: PMCF1
Post Market Observational Trial for the PerQdisc Nucleus Replacement Device
trial testing PerQdisc in Degenerative Disc Disease. Withdrawn.
31 December 2021
Quick facts
| Lead sponsor | Spinal Stabilization Technologies |
|---|---|
| Status | Withdrawn |
| Study type | OBSERVATIONAL |
| Start date | 31 December 2021 |
| Primary completion | 31 December 2021 |
| Estimated completion | 31 December 2021 |
| Sites | 1 location across Germany |
Drugs / interventions tested
- PerQdisc — full drug profile →
Conditions studied
- Degenerative Disc Disease — all drugs for Degenerative Disc Disease →
- Chronic Low-back Pain — all drugs for Chronic Low-back Pain →
Sponsor
Spinal Stabilization Technologies — full company profile →
Who can join
Adults 21 to 60, any sex, with Degenerative Disc Disease or Chronic Low-back Pain. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
PerQdisc PMCF1 is a post-market clinical follow-up observational trial to follow subjects receiving a PerQdisc spinal implant for a duration of 5 years.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT05105490
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of PerQdisc
Trials testing the same drug.
- NCT06860867 — PerQdisc Traditional Feasibility Trial. · NA · recruiting
Other recruiting trials for Degenerative Disc Disease
Currently open trials in the same condition.
- NCT07254806 — A Study to Evaluate the Effectiveness of IDCT (Intradiscal Cell Therapy) in Subjects With One Level, Symptomatic Mild to · Phase 3 · recruiting
- NCT04679844 — Post Marketing Study of MagnetOs Easypack Putty Standalone Compared to Demineralized Bone Matrix or Fibers Mixed With Au · NA · recruiting
- NCT06704919 — Conduit Cages and Fibergraft BG Putty · recruiting
- NCT06053242 — Safety, Tolerability, and Effectiveness of Intramuscular Injection of CELZ-201-DDT for the Treatment of Chronic Lower Ba · Phase 1, PHASE2 · recruiting
- NCT03810573 — Evaluation of NB1 Bone Graft Following Lumbar Interbody Arthrodesis · NA · recruiting
Other Spinal Stabilization Technologies trials
Trials by the same sponsor.
- NCT06860867 — PerQdisc Traditional Feasibility Trial. · NA · recruiting
- NCT05732818 — Lumbar Operatively Inserted PerQdisc Artificial Implant Following Nuclectomy 3 · NA · suspended
- NCT05508360 — "Lumbar Operatively Inserted PerQdisc Artificial Implant Following Nulcectomy" (LOPAIN2) · NA · recruiting
- NCT04141098 — Lumbar Operatively Inserted PerQdisc Artificial Implant Following Nuclectomy · NA · terminated
- NCT04004156 — Safety Study for An Artificial Disc Nucleus Replacement to Treat Chronic Low Back Pain · NA · terminated
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05105490 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Spinal Stabilization Technologies
- Last refreshed: 21 May 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05105490.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing